Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

Background Ten patients with breast cancer and a breast cancer susceptibility gene 1 (BRCA1) mutation, who presented with stages I to III breast cancer between December 2006 and 2007, were treated with four cycles of neoadjuvant cisplatin, followed by mastectomy and conventional chemotherapy. Method...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2009-05, Vol.115 (2), p.359-363
Main Authors: Byrski, T, Huzarski, T, Dent, R, Gronwald, J, Zuziak, D, Cybulski, C, Kladny, J, Gorski, B, Lubinski, J, Narod, S. A
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Cancer research
Cancer therapies
Chemotherapy
Cisplatin - therapeutic use
Clinical Trial
Clinical trials
Female
Genes
Genetic Predisposition to Disease
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Mastectomy
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Mutation
Neoadjuvant Therapy - methods
Oncology
Tumors
Ubiquitin-Protein Ligases - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Ten patients with breast cancer and a breast cancer susceptibility gene 1 (BRCA1) mutation, who presented with stages I to III breast cancer between December 2006 and 2007, were treated with four cycles of neoadjuvant cisplatin, followed by mastectomy and conventional chemotherapy. Methods The excised breast tissue and lymph nodes were examined for the presence of residual disease. Results Pathologic complete response was observed in nine patients (90%). Conclusions Platinum-based chemotherapy appears to be effective in a high proportion of patients with BRCA1-associated breast cancers. Clinical trials are now warranted to determine the optimum treatment for this subgroup of breast cancer patients.
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-008-0128-9